0001447362-21-000166.txt : 20210716 0001447362-21-000166.hdr.sgml : 20210716 20210716105029 ACCESSION NUMBER: 0001447362-21-000166 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20210714 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20210716 DATE AS OF CHANGE: 20210716 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CASTLE BIOSCIENCES INC CENTRAL INDEX KEY: 0001447362 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 770701774 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38984 FILM NUMBER: 211094542 BUSINESS ADDRESS: STREET 1: 505 S FRIENDSWOOD DRIVE STREET 2: SUITE 401 CITY: FRIENDSWOOD STATE: TX ZIP: 77546 BUSINESS PHONE: 866-788-9007 MAIL ADDRESS: STREET 1: 505 S FRIENDSWOOD DRIVE STREET 2: SUITE 401 CITY: FRIENDSWOOD STATE: TX ZIP: 77546 8-K 1 cstl-20210714.htm 8-K cstl-20210714
0001447362FALSE00014473622021-07-142021-07-14

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 14, 2021

Castle Biosciences, Inc.
(Exact name of registrant as specified in its charter) 
     
Delaware 001-38984 77-0701774
(state or other jurisdiction
of incorporation)
 (Commission
File Number)
 (I.R.S. Employer
Identification No.)
505 S. Friendswood Drive, Suite 401
Friendswood, Texas
77546
(Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code: (866) 788-9007

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 
 
Securities registered pursuant to Section 12(b) of the Act: 
Title of each classTrading Symbol(s) Name of each exchange on which registered
Common Stock, $0.001 par value per shareCSTL The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).
Emerging growth company 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  




Item 5.02    Departure of Directors of Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 14, 2021, upon recommendation of the Nominating and Corporate Governance Committee of the board of directors (the “Board”) of Castle Biosciences, Inc. (the “Company”), the Board appointed (i) Kimberlee Caple to serve as a Class III director until the Company’s 2022 annual meeting of stockholders and (ii) Ellen Goldberg to serve as a Class I director until the Company’s 2023 annual meeting of stockholders.

Ms. Caple and Ms. Goldberg will each receive compensation for their service as directors in accordance with the Company’s Non-Employee Director Compensation Policy, as currently in effect (the “Compensation Policy”). The Compensation Policy provides for annual cash compensation of $40,000 for service on the Board, payable in equal quarterly installments and pro-rated for any partial months of service. In addition, pursuant to the Compensation Policy, on July 14, 2021, each of Ms. Caple and Ms. Goldberg were granted an option to purchase 5,365 shares of the Company’s common stock and restricted stock units covering 1,320 shares of common stock. One-third of the shares subject to the stock options vest on July 14, 2022 and the remaining shares shall vest in equal monthly installments over the next two years. The shares subject to the restricted stock units shall vest in a series of three successive equal annual installments over the three-year period measured from the date of the grant. In addition, each of Ms. Caple and Ms. Goldberg have entered into the Company’s standard form of indemnification agreement for its directors and executive officers.

There is no arrangement or understanding between any of Ms. Caple or Ms. Goldberg and any other person pursuant to which Ms. Caple and Ms. Goldberg were appointed as directors. There are no transactions between the Company and any of Ms. Caple or Ms. Goldberg that would require disclosure under Item 404(a) of Regulation S-K.




SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CASTLE BIOSCIENCES, INC.
By:/s/ Derek J. Maetzold
Derek J. Maetzold
President and Chief Executive Officer
Date: July 16, 2021
 



EX-101.SCH 2 cstl-20210714.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 cstl-20210714_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Document Type Document Type Entity Address, Postal Zip Code Entity Address, Postal Zip Code Local Phone Number Local Phone Number Amendment Flag Amendment Flag Written Communications Written Communications City Area Code City Area Code Title of 12(b) Security Title of 12(b) Security Entity Address, State or Province Entity Address, State or Province Security Exchange Name Security Exchange Name Soliciting Material Soliciting Material Document Period End Date Document Period End Date Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Cover [Abstract] Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Pre-commencement Tender Offer Entity Address, Address Line One Entity Address, Address Line One Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Address Line Two Entity Address, Address Line Two Entity Emerging Growth Company Entity Emerging Growth Company Entity Registrant Name Entity Registrant Name Entity File Number Entity File Number Entity Central Index Key Entity Central Index Key Trading Symbol Trading Symbol Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 4 cstl-20210714_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 5 cstl-20210714_htm.xml IDEA: XBRL DOCUMENT 0001447362 2021-07-14 2021-07-14 0001447362 false 8-K 2021-07-14 Castle Biosciences, Inc. DE 001-38984 77-0701774 505 S. Friendswood Drive Suite 401 Friendswood TX 77546 866 788-9007 false false false false Common Stock, $0.001 par value per share CSTL NASDAQ true false XML 6 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover
Jul. 14, 2021
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jul. 14, 2021
Entity Registrant Name Castle Biosciences, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-38984
Entity Tax Identification Number 77-0701774
Entity Address, Address Line One 505 S. Friendswood Drive
Entity Address, Address Line Two Suite 401
Entity Address, City or Town Friendswood
Entity Address, State or Province TX
Entity Address, Postal Zip Code 77546
City Area Code 866
Local Phone Number 788-9007
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 par value per share
Trading Symbol CSTL
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity Central Index Key 0001447362
Amendment Flag false
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Sheet http://www.castlebiosciences.com/role/Cover Cover Cover 1 false false All Reports Book All Reports cstl-20210714.htm cstl-20210714.xsd cstl-20210714_lab.xml cstl-20210714_pre.xml http://xbrl.sec.gov/dei/2020-01-31 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "cstl-20210714.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "cstl-20210714.htm" ] }, "labelLink": { "local": [ "cstl-20210714_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "cstl-20210714_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "cstl-20210714.xsd" ], "remote": [ "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "cstl", "nsuri": "http://www.castlebiosciences.com/20210714", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cstl-20210714.htm", "contextRef": "i87cceed876064885a4766b39720ebffd_D20210714-20210714", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://www.castlebiosciences.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cstl-20210714.htm", "contextRef": "i87cceed876064885a4766b39720ebffd_D20210714-20210714", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.castlebiosciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.castlebiosciences.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.castlebiosciences.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.castlebiosciences.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.castlebiosciences.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.castlebiosciences.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.castlebiosciences.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.castlebiosciences.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.castlebiosciences.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.castlebiosciences.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.castlebiosciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.castlebiosciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.castlebiosciences.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.castlebiosciences.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.castlebiosciences.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.castlebiosciences.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.castlebiosciences.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.castlebiosciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.castlebiosciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.castlebiosciences.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.castlebiosciences.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.castlebiosciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.castlebiosciences.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.castlebiosciences.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 13 0001447362-21-000166-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001447362-21-000166-xbrl.zip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